enGene Therapeutics Inc. (ENGN) EBITDA
- 2026-07-31: Basis Reported; EBITDA -$33.91M*; Operating income -$34.01M; Depreciation and amortization $100.00K.
- 2026-04-30: Basis Reported; EBITDA -$31.77M; Operating income (m); Depreciation and amortization (m).
- 2026-01-31: Basis Reported; EBITDA -$31M; Operating income (m); Depreciation and amortization (m).
- 2025-10-31: Basis Reported; EBITDA -$39.28M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2022-10-31 to 2026-04-30
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-07-31 | Reported | -$33.91M* | -$34.01M | $100.00K | (m) | (m) | $0.00* | -$18.95M* | (m) | $20.09M | (m) | $0.00 |
|---|
| 2026-04-30 | Reported | -$31.77M | (m) | (m) | (m) | (m) | $98.00K* | -$30.50M* | (m) | $22.20M | (m) | $0.00 |
|---|
| 2026-01-31 | Reported | -$31M | (m) | (m) | (m) | (m) | $153.00K | -$28.90M | (m) | $22.25M | (m) | $0.00 |
|---|
| 2025-10-31 | Reported | -$39.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-07-31 | Reported | -$29.85M | (m) | (m) | (m) | (m) | $704.00K* | -$25.63M* | (m) | $22.57M | (m) | $239.00K |
|---|
| 2025-04-30 | Reported | -$27.02M | (m) | (m) | (m) | (m) | $45.00K* | -$22.95M* | (m) | $20.21M | (m) | $240.00K |
|---|
| 2025-01-31 | Reported | -$26.51M | (m) | (m) | (m) | (m) | $299.00K | -$25.70M | (m) | $19.97M | (m) | $18.00K |
|---|
| 2024-10-31 | Reported | -$17.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-07-31 | Reported | -$16.66M | (m) | (m) | (m) | (m) | $2.00K* | -$7.18M* | (m) | $11.55M | (m) | -$29.00K |
|---|
| 2024-04-30 | Reported | -$17.21M | (m) | (m) | (m) | (m) | $179.00K* | -$14.16M* | (m) | $9.86M | (m) | $21.00K |
|---|
| 2024-01-31 | Reported | -$10.69M | (m) | (m) | (m) | (m) | $506.00K | -$7.37M | (m) | $5.64M | (m) | -$30.00K |
|---|
| 2023-10-31 | Reported | -$10.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-07-31 | Reported | -$6.21M | (m) | (m) | (m) | (m) | $157.00K* | -$7.30M* | (m) | $3.90M | (m) | $0.00 |
|---|
| 2023-04-30 | Reported | -$4.7M | (m) | (m) | (m) | (m) | $10.00K* | -$4.44M* | (m) | $3.21M | (m) | $0.00 |
|---|
| 2023-01-31 | Reported | -$4.59M | (m) | (m) | (m) | (m) | $13.00K | -$6.22M | (m) | $3.67M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-10-31 | Reported | -$122.67M | (m) | (m) | (m) | (m) | $1.49M | -$99.24M | (m) | $94.48M | (m) | $0.00 |
|---|
| 2024-10-31 | Reported | -$62M | (m) | (m) | (m) | (m) | $925.00K | -$48.28M | (m) | $38.31M | (m) | -$19.00K |
|---|
| 2023-10-31 | Reported | -$25.86M | (m) | (m) | (m) | (m) | $318.00K | -$24.74M | (m) | $16.46M | (m) | $17.00K |
|---|
| 2022-10-31 | Reported | -$19.23M | (m) | (m) | (m) | (m) | $153.00K | -$17.59M | (m) | $15.47M | (m) | $22.00K |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
|---|
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
|---|
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
|---|
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
|---|